

V P Bondarev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/704562/publications.pdf>

Version: 2024-02-01

24
papers

31
citations

2258059

3
h-index

2053705

5
g-index

24
all docs

24
docs citations

24
times ranked

38
citing authors

#	ARTICLE	IF	CITATIONS
1	Recommendations on the certification of reference standards for structure identification of recombinant therapeutic proteins. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2022, 22, 218-225.	0.5	2
2	Comparative Analysis of Approaches to Assess the Quality of Inactivated Influenza Vaccines: Regulatory Requirements in the Russian Federation and European Union. <i>Epidemiologiya i Vaktsinoprofilaktika</i> , 2021, 19, 36-47.	0.8	0
3	Analysis of the mechanisms of development of the immune response in hepatitis B virus infection and ways to improve the effectiveness of vaccination. <i>Immunologiya</i> , 2021, 42, 403-414.	0.3	3
4	Factor VIII products: key aspects of development, clinical research and use (part 1). <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2021, 21, 39-49.	0.5	1
5	General characteristics of adjuvants and their mechanisms of action (part 2). <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2021, 21, 20-30.	0.5	1
6	Factor VIII products: key aspects of development, clinical research and use (part 2). <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2021, 21, 97-107.	0.5	0
7	Vaccine interchangeability: problems and prospects. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2021, 21, 142-157.	0.5	1
8	Problems associated with the manifestation of immunogenicity of biotherapeutic proteins and ways to solve them. <i>Immunologiya</i> , 2021, 42, 706-719.	0.3	0
9	Review of global use of licensed vaccines and development of new vaccines for the prevention of pneumococcal infection. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2021, 21, 234-243.	0.5	0
10	General Considerations on Clinical Trials of Hemophilia Medicines. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2020, 20, 30-41.	0.5	1
11	Russian and International Regulatory Recommendations for the Development and Marketing Authorisation of COVID-19 Vaccines in the Context of the Pandemic. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2020, 20, 228-244.	0.5	1
12	Principles for clinical trials of coagulation factor IX products. <i>Pacific Medical Journal</i> , 2020, , 11-18.	0.3	0
13	Post-approval Variations to Dossiers for Vaccines: Analysis of Regulatory and Methodological Approaches Used in the Russian Federation and Abroad. <i>The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products</i> , 2019, 9, 41-48.	0.2	2
14	Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2019, 19, 17-27.	0.5	0
15	Rotavirus Epidemiology and Vaccination Tactics. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2019, 19, 81-87.	0.5	3
16	Special Considerations on the Use of Vaccines for Immunoprophylaxis of Bacterial Infections. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2019, 19, 145-153.	0.5	0
17	The Current Use of Biomedical Cell Products for Cancer Treatment. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2019, 19, 206-214.	0.5	2
18	Development of an Industrial Reference Sample for the Specific Activity of Erythropoietin. <i>Pharmaceutical Chemistry Journal</i> , 2018, 52, 90-94.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Genome-Editing and Biomedical Cell Products: Current State, Safety and Efficacy. BIOpreparations Prevention Diagnosis Treatment, 2018, 18, 140-149.	0.5	5
20	Critical Development Needs for Recombinant Blood-Coagulation Factors. Pharmaceutical Chemistry Journal, 2016, 50, 573-576.	0.8	0
21	Epidemiological aspects of meningococcal infection and problems of vaccine prophylaxis. Infektsionnye Bolezni, 2016, 14, 55-64.	0.4	2
22	Experimental study of biological and biomechanical compatibility of nanostructured spiral stent. Novosti Khirurgii, 2014, 22, 654-664.	0.2	0
23	Development of monoclonal antibodies to highly pathogenic avian influenza H5N1 virus and their application to diagnostics, prophylaxis, and therapy. Acta Virologica, 2011, 55, 3-14.	0.8	7
24	Promising opportunities to improve polio vaccines. BIOpreparations Prevention Diagnosis Treatment, 0, , .	0.5	0